Introduction
Screening is the main strategy for secondary prevention of uterine cervical cancer. Cytological screening, Pap test, has led to a significant reduction in the incidence of and mortality from cervical cancer [1] .
Conventional Pap test was introduced into Korea in the late 1950's and has contributed to early detection of precancerous lesions and cervical cancer. Korean National Cancer Screening Program recommends that women of age 30 or more receive the Pap test biannually, whereas the Korean Society of Obstetrics and Gynecology recommends that women of age 20 or more receive the test annually [2] .
Although Pap test has the merit of being convenient, reasonably specific and inexpensive, the sensitivity have been questioned. A low sensitivity of Pap test would put women at risk to develop invasive cervical cancer. Considerable variation in the sensitivity and specificity of Pap test has been reported [3] . In attempt to improve sample quality, interest has shifted to use liquid-based cytology (LBC). Although not included as a screening method in Korea, LBC has been rapidly popular among clinicians.
In view of the importance of human papillomavirus (HPV) in the etiology of cervical cancer, HPV DNA testing to allow women to be classified as high-risk HPV-positive or negative could be used as an adjunct to Pap test. Currently there is no recommendation for HPV testing in cervical cancer screening guidelines. However, the National Health Insurance Corporation has approved HPV testing to confirm cervical dysplasia or carcinoma resulting from an abnormal Pap.
Estimations sensitivity and specificity of screening test are important because they may be used to determine policy decisions, such as recommendations for optimal frequency of screening, management of mild abnormalities, and use of newer methods. To compare the accuracy of Pap test and other alternative screening tools (i.e., LBC and HPV testing), Korean studies that reported accuracy of each screening methods were intensively reviewed and the pooled estimates for sensitivity and specificity was calculated by meta-analysis.
Materials and methods
Articles published between 1995 and March 2008 were retrieved from the electronic bibliographic databases, MEDLINE and KoreaMed, using the following search terms (pap OR liquid OR cytology OR HPV) AND (sensitivity OR accuracy), AND (Korea OR Korean) for MEDLINE. Articles written in Korean or English were included.
For the meta-analysis, the threshold for the defini- However, HPV DNA Chips (Biomedlab or MyGene, Korea) have been widely used in clinics recently and additionally included in the meta-analysis. All of these thresholds, standard of true disease and inclusion criteria were used in the international systematic reviews and meta-analyses of cervical cancer screening [4, 5] .
Meta-DiSc version 1.4, software which developed for meta-analysis of test accuracy data [6] was used. Sensitivity and specificity was pooled by the Der Simonian Laird method (random effects model) to incorporated variation among studies and computed a weighted average. Table  Table Table  Table 1. 1. 1. 1. Sensitivity and specificity of conventional Pap test, liquid-based cytology and HPV DNA testing (Korean studies) Table  Table Table  Table 1 that specimens were collected with inadequate tool (i.e., cotton swab) [7] and completely duplicated [8] with a previous literature [9] were excluded to review. Table 1 is a summary table containing study population, year at sample recruitment, prevalence of cytologic abnormalities or HPV positivity in study population, cytologic cutoff, detection level, sensitivity and specificity of each screening method, and brand name of LBC or HPV testing. Sensitivity and specificity of each screening method was widely divergent among individual studies. Moreover, cytologic cutoffs, detection levels and test kit manufactures were also varied ( Table 1) . Sensitivity of Pap test was varied from 53.4% to 94.0%, and specificity was 43.6%-97.0% . Although it was also varied among individual studies, sensitivity (76.4%-94.9%) and specificity (66.0% to 98.3%) of LBC were relatively higher than those of Pap test. Sensitivity and specificity of HPV test were 57.8%-95.8% and 37.4%-93.1%, respectively. Generally, sensitivity and specificity of LBC were relatively higher than those of Pap test. Sensitivity of HPV DNA test was higher than that of Pap test but specificity was lower.
Results
There were 15 studies on Pap test [11-15,17-19, 22,23,25-27,29,30] , 3 studies on LBC [17, 19, 30] and 4 studies on HPV [13, 22, 25, 30] , which met the criteria for meta-analysis. As shown in Figure 1 and Figure  2 , pooled sensitivity and specificity of Pap test for CIN2+ was 76% (95% CI=75%-78%) and 76% (95% CI=75%-77%), respectively. However, significant heterogeneity was observed across studies (p<0.0001) (Fig. 1, Fig. 2) . Table 2 shows pooled accuracy of each screening methods. Pooled sensitivity and specificity of LBC (i.e., ThinPrep & SurePath) for CIN2+ was 92% (95% CI=90%-94%) and 79% (95% CI=76%-81%), respectively. Pooled sensitivity and specificity of HPV testing (i.e., HC2) for CIN2+ was 83% (95% CI=80% -86%) and 59% (95% CI=55%-63%), respectively. There was significant heterogeneity among these studies' results (p<0.0001), except for pooled sensitivity of LBC (P=0.682).
When the two HPV testing methods, HC2 [13, 22, 25, 30] and HPV DNA Chip [24, 31] , were pooled together, pooled sensitivity and specificity was not ig. Fig. Fig.  Fig. 1 significantly different between two methods (data not shown).
Discussion
Uterine cervical cancer is one of the major cancers in Korean women. According to a recent report of Korean Central Cancer Registry, Cervical cancer accounted for 6.5% of new cancer cases from 2003 to 2005 and approximately 4,000 invasive cervical cancer cases (ICC) and 4,000 cervical carcinoma in situ (CIS) were diagnosed in each year. The agestandardized incidence rate for cervical cancer steadily declined from 19 per 100,000 women in 1993 to 13 per 100,000 women in 2005 [32] . The Korean National Statistical Office reported that 987 women died from cervical cancer in 2007 [33] . The age-standardized cervical cancer mortality rate also declined from 5.2 to 3.9 in 100,000 women in last decade [34] . On the other hand, the overall five-year relative survival rate for cervical cancer patients was steadily increased from 77.5% (in 1993-1995) to 81.1% (in 2001-2005) [32] .
Overall, the decreased incidence and mortality rates of cervical cancer and increased survival rates ig. Fig. Fig.  Fig. 2 Table  Table Table  Table 2. 2. 2.
Pooled accuracy for detection CIN2+
are probably due to the introduction of screening programs and effective treatment [35, 36] . Cervical cancer screening using the Pap test was first introduced in the late 1950s and became more widely used in the 1980s. The overall participation rate including both opportunistic and national organized screening was estimated at 73.6% in 2007 [37] . Although cervical cancer screening is widely expanded, the screening quality is questionable. Factors limiting sensitivity of conventional Pap testing include small lesion size, inadequate sampling, obscuring blood and debris, and variability of individual results. Considerable variation in the sensitivity and specificity of Pap test has been reported [3] . In this review of 23 Korean literatures, sensitivity of Pap test was varied from 53.4% to 94.0%. LBC is supposed to have a number of advantages over conventional Pap test. These include a more representative transfer of cells from the collection device to the glass slide, a reduction in the number of unsatisfactory cytology specimens, the availability of residual cellular material for subsequent molecular testing or for making additional glass slides, and possibly increased detection of abnormal cytology. Many developed countries use LBC as a primary cervical cancer screening tool based on cost-effectiveness [38] . Despite of these advantages of LBC, majority of Korean clinicians prefer conventional Pap test to LBC because the price of conventional Pap test is much lower than of LBC [39] . In this meta-analysis, sensitivity and specificity of LBC was higher than those of Pap or HPV testing. In contrast with general understanding about higher sensitivity of LBC than of Pap test, a most recent literature of systematic review on diagnostic accuracy of Pap test and LBC reported that the pooled sensitivity of Pap test and LBC was not significantly different, and specificity was similar [4] . The pooled sensitivity of Pap test and LBC at ASCUS threshold for CIN2 or worse was 88.2% (95% CI=80.2%-93.2%) and 90.4% (95% CI=82.5%-95.0%), respectively. The pooled specificity of Pap test and LBC at ASCUS threshold for CIN2 or worse was 71.3% (95% CI= 58.3%-81.6%) and 64.6% (95% CI= 50.1%-76.8%), respectively.
According to dozens of large-scale clinical studies, sensitivity and specificity of HPV testing in primary screening for cervical cancer and its precancer lesions varied 46%-100% and 52%-96%, respectively, and generally higher than those of cytology [40] . HPV testing has shown to be an efficient alternative to repeated cytology in cases of uncertainty in the reading of Pap test, and is an appropriate way to follow women after treatment for abnormal cervical lesions. HPV testing has shown to provide clinically meaningful evidence to guide management of HPV positive women with normal cytology without compromising safety.
According to a most recent literature of systematic review conducted following the Cochrane Collaboration Guidelines, the pooled sensitivity of HPV DNA test (90.0%, 95% CI=86.4%-93.7%) was significantly higher than cytology (72.7%, 95% CI=63.9%-81.5%, at threshold of ASCUS), whereas the pooled specificity of HPV DNA test (86.5%, 95% CI=83.1%-89.8%) was significantly lower than cytology (91.9%, 95% CI=90.2%-93.6%, at threshold of ASCUS) [5] . In countries where cytology is of good quality, it has been suggested that HPV testing as the sole screening modality with cytology reserved for triage of HPVpositive women [41] . The most important obstacles to more widespread acceptance of HPV testing in cervical cancer screening are its high cost and the fact that the technology is not in the public domain, as it is for cervical cytology.
In this meta-analysis, the pooled sensitivity and pooled specificity of Pap test were both 76%. However these may have some difference from real accuracy of cervical cancer screening in Korea for several reasons. First, study subjects were highly selected high-risk group because they mostly referred women for further evaluation with abnormal cytology in primary cervical screening. Prevalence of abnormal cytology (12-83%) or HPV infection (4-91%) in study women was much higher than in general population (abnormal cytology 5%; HPV infection 10%, appro-ximately) [42] [43] [44] . In most studies, the presence or absence of disease was not verified with colposcopy and histology in all women who attend primary screening leading to potential verification bias. It is likely that false negative results are missed for either test without adequate verification of test negative. This causes an overestimation of the sensitivity or false positivity rate.
Second, the sensitivity and specificity of Pap test in local clinics may be lower than in these studies because most of these studies were conducted in university hospitals with high quality health professionals and well-trained laboratory personals. Actually, more than 60% of cervical cytology have been tested in commercial laboratories, which have limited pathologists and laboratory personals [45] .
Third, although error occurs at the beginning of cervical specimen collection and one of the advantages of LBC is to reduce inadequate specimens than in conventional Pap test, all 24 reviewed studies did not included inadequate specimens for their analysis. Sensitivity of Pap test in real setting possibly lower than the pooled sensitivity, 76%, for these reasons.
Fourth, the number of studies on LBC or HPV testing included in this meta-analysis was small and these studies conducted in recently compared to studies on Pap test. The accuracy of LBC or HPV testing is possibly higher than of Pap test because these new technologies have been recently equipped and the laboratory personals also have been recently trained. In contrast, Pap test has been widely used for several decades and the studies included in this meta-analysis were based on relatively older data than LBC or HPV testing.
Finally, significant heterogeneity was observed across studies in the meta-analysis (p<0.0001), excepting for pooled sensitivity of LBC (P=0.682), and subgroup analysis was not possible. Therefore, the pooled sensitivity and pooled specificity in this meta-analysis have limit to present accuracy of Pap test, LBC and HPV testing as a primary cervical cancer screening tools in Korea.
In conclusion, because enhancing cervical cancer screening coverage and improving the quality of cervical cancer screening are part of an important strategy for secondary prevention [46] , accuracy and cost-effectiveness of cervical cancer screening methods should be further evaluated.
